June 2, 2016
American Society of Clinical Oncology, Inc. (ASCO®) and the Conquer Cancer Foundation® (CCF) continue to recognize the donors whose generous contributions are making the vision of CancerLinQ™ a reality. In this latest installment, ASCO® and CCF recognize Janssen Oncology and HELSINN for their commitment to collaboration in the field of oncology. These donations will help ensure that CancerLinQ™, a powerful platform containing growing amounts of real-world cancer information can provide new tools to provide quality care. CancerLinQ™ is developed by CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology, Inc. (ASCO®).
Inspired by the words of founder, Dr. Paul Janssen, “There is so much more to be done; the patients are waiting,” Janssen Oncology is driven by the urgency around finding new ways to prevent and treat cancer. This led to their support of CancerLinQ™, a program that has the potential to considerably advance the understanding of cancer by aggregating important insights.
“The information provided by CancerLinQ will drive the treatment options of tomorrow and improve the quality of care to our cancer patients. This information will be based from not only patients involved in clinical trials but more importantly the oncology patients treated in all regions and settings of the country,” stated Dr. Andree Amelsberg, Vice President of Janssen Oncology Medical Affairs. “It is quite incredible to think about garnering evidence from millions of patients versus just a small fraction of them.”
As Janssen Oncology embarks on new treatment modalities, their support of CancerLinQ™ will aid in their mission to conquer cancer. Janssen believes the collaborative efforts of all health care partners are required to translate today’s science advances into real-world evidence.
Helsinn, the Swiss pharmaceutical group focused on building quality cancer care, with headquarters in Lugano, Switzerland and subsidiaries in U.S.A., Ireland, and a representative office in China, is committed to improving the everyday lives of people with cancer, guided by core family values of respect, integrity and quality. Helsinn’s commitment to these principles has led to its support for CancerLinQ™.
“At Helsinn, we believe that CancerLinQ will become the database of excellence in the oncology therapeutic field,” said Riccardo Braglia, Helsinn Group Vice-Chairman and CEO. According to Mr. Braglia, Helsinn expects that CancerLinQ™ will reduce the potential for suboptimal treatment and allow patients to benefit from insights much sooner than otherwise possible.
“The system has the potential to help patients find the most effective treatment options, including access to novel clinical trials.” said Mr. Braglia.
CancerLinQ™ is supported in part through the Conquer Cancer Foundation of the American Society of Clinical Oncology, Inc., whose generous donors have helped make CancerLinQ possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Raj Mantena, RPh; Novartis Oncology; Pfizer Oncology; Thomas G. Roberts, Jr., MD and Susan M. DaSilva; and Susan G. Komen®.